Overview
- The vaccine should not be used in people aged 60 or over or in anyone with high blood pressure, heart disease, diabetes, or chronic kidney disease.
- Use is also contraindicated in individuals who are immunodeficient or immunosuppressed, including IgA deficiency, and in those with a history of thymus disorder or thymectomy.
- Healthcare professionals must conduct comprehensive benefit–risk assessments before offering IXCHIQ and exercise caution for patients with two or more chronic conditions.
- As a precaution, vaccination is advised at least 30 days before travel so any serious reaction occurs while the person has access to UK healthcare.
- MHRA will update patient information and urges reporting of side effects via the Yellow Card scheme, formalizing a June 2025 pause after a safety review.